Published September 19, 2024

At Pheiron, we use AI to integrate multi-omic data and accurately capture disease pathophysiology accurately in AI-driven biomarkers. One key application of our AI-biomarkers is in enhancing the evidence generated from RCTs and real-world observational studies. Here we validated and applied one of our AI-biomarkers, an algorithm predicting cardiovascular risk from 12-lead ECGs in collaboration with DandelionHealth.

Published November 10, 2025

Pheiron presented new findings at the American Heart Association (AHA) Scientific Sessions 2025 demonstrating genetic evidence that simultaneous reduction of lipoprotein(a) [Lp(a)] and PCSK9 may deliver additive risk reduction in atherosclerotic cardiovascular disease (ASCVD). The analysis integrates large-scale human genetics with AI-driven phenotyping across population-scale biobanks.

Fri Feb 16 2024 09:54:57 GMT+0000 (Coordinated Universal Time)

Drug development is broken: Over 90% of drug development programs entering clinical development fail, costing the industry an average of $6.16bn for a novel approved drug. The root of the problem? Insufficient evidence to anticipate clinical efficacy. We build Pheiron to change that - in silico and at scale.